[Hypoparathyroidism].
Hypoparathyroidism and quality of life: Even in adequately substituted patients, hypoparathyroidism (HPT) is associated with impaired quality of life. It has been hypothesized that there is a correlation between reduced quality of life and lack of parathyroid hormone (PTH) in the central nervous system. Positive effects on quality of life have been reported when treating HPT with PTH. Hypoparathyroidism and comorbidities: Comorbidities associated with HPT include an increased risk of nephrolithiasis/nephrocalcinosis and neuro-psychiatric disease. Additionally, cardiovascular risk profile and an increased susceptibility for infections have been reported. Mortality rates seem not to be increased in HPT. Hypoparathyroidism and new therapeutic strategies: Recombinant PTH has not been approved for the treatment of HPT in Europe yet. However, in early 2015, the FDA approved PTH (1-84). Daily subcutaneous delivery of PTH (1-84) and PTH (1-34) (Teriparatide) has emerged as a promising therapeutic tool. However, its use should be restricted to patients insufficiently controlled with the standard treatment consisting of active vitamin d and calcium.
Medizinische Klinik und Poliklinik, Schwerpunkt Endokrinologie und Diabetologie, Universitätsklinikum Würzburg.
Ann-Cathrin
AC
Koschker
Medizinische Klinik und Poliklinik, Schwerpunkt Endokrinologie und Diabetologie, Universitätsklinikum Würzburg.
Stephanie
S
Burger-Stritt
Medizinische Klinik und Poliklinik, Schwerpunkt Endokrinologie und Diabetologie, Universitätsklinikum Würzburg.
Stefanie
S
Hahner
D015897:Comorbidity; D004334:Drug Administration Schedule; D017277:Drug Approval; D005858:Germany; D006801:Humans; D007011:Hypoparathyroidism / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D007279:Injections, Subcutaneous; D044162:Parathyroid Hormone-Related Protein / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D019379:Teriparatide / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D011994:Recombinant Proteins; D019379:Teriparatide; C066077:parathyroid hormone-related protein (1-84)